4 research outputs found

    Atividade antinociceptiva orofacial do (S)-(-)-ĂĄlcool perĂ­lico em camundongos: um estudo controlado, randomizado e triplo-cego

    Get PDF
    Monoterpenes are the major bioactive compounds found in essential oils from medicinal plants used in the treatment of diseases. Among these, (S)-(-)-perillyl alcohol (PA) stands as a promising molecule with antitumor, anti-inflammatory and antioxidant properties. This study investigated the antinociceptive effects of PA on orofacial nociception in Swiss male mice using tests of formalin-, capsaicin-, and glutamate-induced pain. For each test, eight animals per group were pretreated intraperitoneally by a blinded investigator with PA (50 and 75 mg/kg, i.p.), morphine (5 mg/kg, i.p.) or vehicle (saline + 0.2% Tween 80). The treatment was performed thirty minutes before the induction of orofacial nociception by injecting formalin (20 ”l, 2%), capsaicin (20 ”l, 2.5 ”g) or glutamate (40 ”l, 25 mM) solution in the right area of the upper lip. The orofacial nociceptive behavior was timed in all tests by an investigator blinded to the treatments. Statistical analysis was performed by a blinded researcher. Groups were compared with Mann-Whitney’s test and the correlation was calculated with Spearman’s correlation test, describing its median and interquartile range. The magnitude of statistical analysis was also analyzed with confidence intervals, effect size and power. The results indicate that PA blocked the orofacial nociceptive behavior at all tested doses (P .05) in the formalin, capsaicin and glutamate tests. Effect size was high in phase I of formalin test for 50 mg/kg and 75 mg/kg of PA (CI95%: 2,32/0,48; power: 84% and CI95%: 2,76/0,82; power: 96.2%, respectively), 75 mg/kg of PA in phase II (CI95%: 2,26/0,44; power: 82.3%) and for 75 mg/kg of PA in glutamate test (CI95=3,16/1,11; power: 99.2%). These findings confirm a strong evidence of antinociceptive properties of PA in the orofacial region considering high values of power observed in formalin and glutamate models, suggesting it as a potential substance for the treatment of clinical conditions involving orofacial pain.Os monoterpenos sĂŁo os principais componentes bioativos encontrados em Ăłleos essenciais de plantas com uso medicinal para o tratamento de doenças. Dentre eles, o (S)-(-)-ĂĄlcool perĂ­lico (AP) representa uma molĂ©cula promissora com atividades antitumoral, anti-inflamatĂłria e antioxidantes. O presente estudo investigou os efeitos antinociceptivos do AP na nocicepção orofacial em camundongos suíços utilizando os testes de dor induzida por formalina, capsaicina e glutamato. Para cada teste, oito animais por grupo foram prĂ©-tratados via intraperitoneal (i.p.) por um investigador cego com AP (50 e 57 mg/kg, i.p.), morfina (5 mg/kg, i.p.) ou veĂ­culo (salina + Tween 80 0.2%). O tratamento foi realizado trinta minutos antes da indução da nocicepção orofacial atravĂ©s da injeção de uma solução de formalina (20 ”l, 2%), capsaicina (20 ”l, 2.5”g) ou glutamato (40 ”l, 25 mM) no lĂĄbio superior direito do animal utilizando uma agulha calibre 27G. O tempo de comportamento de nocicepção orofacial foi medido por um investigador cego para os grupos de tratamento, assim como a anĂĄlise estatĂ­stica. Os grupos foram comparados utilizando o teste de Mann-Whitney e a correlação entre as doses foi calculada pelo teste de correlação de Spearman, descrevendo para cada grupo os valores de mediana e distĂąncia interquartil. A magnitude da anĂĄlise estatĂ­stica foi verificada com os intervalos de confiança, magnitude do efeito e poder. Os resultados indicaram que o AP bloqueou o comportamento de nocicepção orofacial em todas as doses testadas (p <,05) de modo similar Ă  morfina (p <,05) nos testes da formalina, capsaicina e glutamato. A magnitude do efeito foi alta para a fase 1 do teste da formalina nas doses de 50 e 75 mg/kg de AP (IC95%: 2,32/0,48; poder: 84% e IC95%: 2,76/0,82; poder: 96,2%, respectivamente), assim como na dose de 75 mg/kg na fase II do teste da formalina (IC95%: 2,26/0,44; poder: 82,3%) e no teste do glutamato (IC95=3,16/1,11; poder: 99,2%). Os testes com AP confirmam uma forte evidĂȘncia de sua atividade antinociceptiva considerando os altos valores de poder principalmente nos modelos da formalina e glutamato, sendo assim uma substĂąncia potencial para o tratamento de condiçÔes clĂ­nicas envolvendo dor orofacial

    Temporomandibular disorder is more prevalent among patients with primary headaches in a tertiary outpatient clinic

    No full text
    Objective The aim of this study was to estimate the prevalence of signs and symptoms of temporomandibular disorders (TMD) in patients with primary headaches attended in a tertiary neurology ambulatory.Method Authorized by the Ethics Committee, the present cross-sectional study was conducted with a random sample of patients screened for orofacial pain and primary headaches at a tertiary hospital in Northeast of Brazil.Results The sample consisted in 42 patients with primary headache, 59.5% male. The prevalence of > 6 TMD signs and symptoms was 54.8%. In those patients with migraine TMD was present in 71.4% and in tension-type headache in 38.1% (p = 0.030; OR = 4.1). TMD was related to the clinical status of headache associated or attributed to medication overuse (p = 0.001).Conclusion TMD has a high prevalence in patients with primary headaches (54.8%). Special attention must be given to patients with migraine and headache associated or attributed to medication overuse
    corecore